BRAF and hairy cell leukemia: BRAF inhibitors (BRAFi) (vemurafenib, dabrafenib, encorafenib) and also mitogen-activated protein kinase (MEK) inhibitors (MEKi) (trametinib, binimetinib) represent effective and promising therapeutic approaches in patients with relapsed/refractory HCL.